☆ 4.4 Article

Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non-Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm

CLINICAL LUNG CANCER (2020)

Get Full Text
Add to Collection

Journal

CLINICAL LUNG CANCER
Volume 21, Issue 1, Pages E1-E5

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2019.07.012

Keywords

Brain metastasis; Checkpoint inhibitor; Immunotherapy; Leptomeningeal carcinomatosis; Nivolumab

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.